| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Rosa L S Soares | |
| P2860 | cites work | Utility of a rapid fecal latex agglutination test detecting the neutrophil protein, lactoferrin, for diagnosing inflammatory causes of chronic diarrhea | Q47676153 |
| Sensitization of peripheral sensory nerves by mediators from colonic biopsies of diarrhea-predominant irritable bowel syndrome patients: a role for PAR2. | Q47746673 | ||
| Statistical validation of endophenotypes using a surrogate endpoint analytic analogue | Q48299287 | ||
| Ismar Boas: father of gastroenterology and founder of the oldest surviving publication in digestive diseases | Q48449961 | ||
| An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. | Q48516420 | ||
| Nongastrointestinal symptoms of irritable bowel syndrome: an office-based clinical survey | Q48554187 | ||
| Repetitive rectal painful distention induces rectal hypersensitivity in patients with irritable bowel syndrome | Q48933328 | ||
| Postinfective diarrhoea and bile acid malabsorption. | Q50136316 | ||
| The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects | Q50171831 | ||
| Utility of red flag symptom exclusions in the diagnosis of irritable bowel syndrome. | Q50730347 | ||
| Evidence of a genetic contribution to functional bowel disorder. | Q50870347 | ||
| Is a negative colonoscopy associated with reassurance or improved health-related quality of life in irritable bowel syndrome? | Q50952427 | ||
| Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. | Q51010528 | ||
| Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. | Q51310014 | ||
| Elevated motility-related transmucosal potential difference in the upper small intestine in the irritable bowel syndrome. | Q51462976 | ||
| Ambulatory 24-hour jejunal motility in diarrhea-predominant irritable bowel syndrome. | Q51581105 | ||
| Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. | Q51660489 | ||
| Faecal lactoferrin--a novel test to differentiate between the irritable and inflamed bowel? | Q51711676 | ||
| Value of different diagnostic criteria for the irritable bowel syndrome among men and women. | Q51718552 | ||
| Gastrointestinal symptoms after infectious diarrhea: a five-year follow-up in a Swedish cohort of adults. | Q51756320 | ||
| Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. | Q51792257 | ||
| Therapeutic value of a gastroenterology consultation in irritable bowel syndrome. | Q51949705 | ||
| Irritable bowel syndrome according to varying diagnostic criteria: are the new Rome II criteria unnecessarily restrictive for research and practice? | Q51971888 | ||
| Treatment of irritable bowel syndrome with osteopathy: results of a randomized controlled pilot study. | Q53179617 | ||
| Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. | Q53264495 | ||
| Altered rectal perception is a biological marker of patients with irritable bowel syndrome. | Q53641269 | ||
| Irritable bowel syndrome and hypersensitivity to food. | Q54064749 | ||
| The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations. | Q54319433 | ||
| Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. | Q54513905 | ||
| Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome | Q56985161 | ||
| Acupuncture for treatment of irritable bowel syndrome | Q24197693 | ||
| Psychological treatments for the management of irritable bowel syndrome | Q24241516 | ||
| Prevalence of irritable bowel syndrome: a community survey | Q24535897 | ||
| Giardia lamblia infection in patients with irritable bowel syndrome and dyspepsia: a prospective study | Q24563002 | ||
| Irritable Bowel Syndrome and Co-morbid Gastrointestinal and Extra-gastrointestinal Functional Syndromes | Q24601623 | ||
| Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome | Q24647883 | ||
| Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis | Q24656989 | ||
| Small intestinal bacterial overgrowth in patients with irritable bowel syndrome | Q24674609 | ||
| Towards positive diagnosis of the irritable bowel | Q24674701 | ||
| Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial | Q24685836 | ||
| Melancholic microbes: a link between gut microbiota and depression? | Q27692537 | ||
| The endophenotype concept in psychiatry: etymology and strategic intentions | Q28187744 | ||
| Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome | Q28238388 | ||
| Genetic influences in irritable bowel syndrome: a twin study | Q28254060 | ||
| A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence | Q28295210 | ||
| Rifaximin therapy for patients with irritable bowel syndrome without constipation | Q28302405 | ||
| Pathways involved in gut mucosal barrier dysfunction induced in adult rats by maternal deprivation: corticotrophin-releasing factor and nerve growth factor interplay | Q28566642 | ||
| Functional bowel disorders | Q29620328 | ||
| Phenotypic changes in colonocytes following acute stress or activation of mast cells in mice: implications for delayed epithelial barrier dysfunction | Q30489893 | ||
| Bacitracin reveals a role for multiple thiol isomerases in platelet function | Q30806590 | ||
| Role of radiologic imaging in irritable bowel syndrome: evidence-based review. | Q31043201 | ||
| Cortical effects of anticipation and endogenous modulation of visceral pain assessed by functional brain MRI in irritable bowel syndrome patients and healthy controls | Q31048975 | ||
| Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome | Q32026613 | ||
| The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects | Q33290848 | ||
| Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome | Q33422637 | ||
| The role of intestinal gas in functional abdominal pain | Q33423659 | ||
| Prokinetic effects in patients with intestinal gas retention | Q33425345 | ||
| Sugar malabsorption in functional abdominal bloating: a pilot study on the long-term effect of dietary treatment | Q33434608 | ||
| Gastrointestinal food hypersensitivity: basic mechanisms of pathophysiology | Q35681602 | ||
| A randomised controlled trial of self-help interventions in patients with a primary care diagnosis of irritable bowel syndrome. | Q35760289 | ||
| Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. | Q35761348 | ||
| Irritable bowel syndrome in the general population | Q35819583 | ||
| Irritable bowel syndrome: a review and update | Q35948222 | ||
| Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity | Q35954099 | ||
| Systematic review: the influence of geography and ethnicity in irritable bowel syndrome | Q36072578 | ||
| Brain-Gut Interactions in IBS | Q36076024 | ||
| The irritable bowel syndrome: review and a graduated multicomponent treatment approach | Q36110395 | ||
| Genetics and genotypes in irritable bowel syndrome: implications for diagnosis and treatment | Q36111352 | ||
| Irritable bowel syndrome: physicians' awareness and patients' experience | Q36121234 | ||
| Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. | Q36160305 | ||
| The genetics of irritable bowel syndrome | Q36306788 | ||
| Irritable bowel syndrome: diagnosis and pathogenesis | Q36310403 | ||
| The role of fiber in the treatment of irritable bowel syndrome: therapeutic recommendations | Q36361490 | ||
| Irritable bowel syndrome: a multidimensional disorder cannot be understood or treated from a unidimensional perspective | Q36379093 | ||
| A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation | Q36417684 | ||
| Pharmacodynamic and clinical endpoints for functional colonic disorders: statistical considerations | Q36487263 | ||
| Irritable bowel syndrome: the burden and unmet needs in Europe | Q36522591 | ||
| Postinfectious irritable bowel syndrome--a meta-analysis | Q36574982 | ||
| Associations between medication use and functional gastrointestinal disorders: a population-based study | Q36780776 | ||
| Intestinal permeability and irritable bowel syndrome | Q36860979 | ||
| Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease | Q36874385 | ||
| A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome | Q36886282 | ||
| Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials | Q36983944 | ||
| Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior | Q37120953 | ||
| Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis | Q37160532 | ||
| Somatic comorbidities of irritable bowel syndrome: a systematic analysis | Q37172176 | ||
| Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment | Q37177507 | ||
| Towards a definition of comorbidity in the light of clinical complexity | Q37188662 | ||
| Cortagine, a CRF1 agonist, induces stresslike alterations of colonic function and visceral hypersensitivity in rodents primarily through peripheral pathways | Q37264524 | ||
| Discrepancies between the responses to skin prick test to food and respiratory antigens in two subtypes of patients with irritable bowel syndrome | Q37265599 | ||
| Protease activated receptor 2: a new target for IBS treatment | Q37299598 | ||
| Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study | Q44318836 | ||
| Long-term success of GUT-directed group hypnosis for patients with refractory irritable bowel syndrome: a randomized controlled trial | Q44404507 | ||
| Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome | Q44505164 | ||
| Prevalence of irritable bowel syndrome in a Brazilian Amazon community | Q44726409 | ||
| The development and maintenance of human visceral pain hypersensitivity is dependent on the N-methyl-D-aspartate receptor | Q44779669 | ||
| Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. | Q44779671 | ||
| Yogic versus conventional treatment in diarrhea-predominant irritable bowel syndrome: a randomized control study | Q44839377 | ||
| A population study on irritable bowel syndrome and mental health | Q45185122 | ||
| Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective | Q46095343 | ||
| Chronic abdominal wall pain: clinical features, health care costs, and long-term outcome | Q46122480 | ||
| Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome | Q46256357 | ||
| Report from the multinational irritable bowel syndrome initiative 2012. | Q46384492 | ||
| The impact of irritable bowel syndrome on health-related quality of life | Q46485395 | ||
| Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-D-xylose and healthy controls | Q46572204 | ||
| Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents | Q46645941 | ||
| Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls | Q46678855 | ||
| Bronchial hyperresponsiveness in irritable bowel syndrome | Q46679828 | ||
| Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity | Q46808316 | ||
| Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity | Q46809151 | ||
| The degree of breath methane production in IBS correlates with the severity of constipation | Q46824948 | ||
| Increased visceral sensitivity in Giardia-induced postinfectious irritable bowel syndrome and functional dyspepsia. Effect of the 5HT3-antagonist ondansetron | Q46921547 | ||
| Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology | Q46928786 | ||
| Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? | Q46939907 | ||
| Altered cognitive function of prefrontal cortex during error feedback in patients with irritable bowel syndrome, based on FMRI and dynamic causal modeling | Q47330645 | ||
| Relationship of abdominal bloating to distention in irritable bowel syndrome and effect of bowel habit | Q33436052 | ||
| Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome | Q33441709 | ||
| Prevalence, comorbidity, and risk factors for functional bowel symptoms: a population-based survey in Northern Norway | Q33456089 | ||
| Loperamide in treatment of irritable bowel syndrome--a double-blind placebo controlled study | Q33471596 | ||
| Importance of early diagnosis in patients with irritable bowel syndrome | Q33536973 | ||
| How does comorbidity affect cost of health care in patients with irritable bowel syndrome? A cohort study in general practice | Q33541333 | ||
| Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome | Q33636450 | ||
| Advances in imaging the brain-gut axis: functional gastrointestinal disorders | Q33774755 | ||
| Food intolerance and skin prick test in treated and untreated irritable bowel syndrome. | Q33868855 | ||
| Pathobiology of visceral pain: molecular mechanisms and therapeutic implications. III. Visceral afferent pathways: a source of new therapeutic targets for abdominal pain. | Q33912707 | ||
| Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts | Q33919357 | ||
| Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial | Q33920479 | ||
| Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials | Q33969643 | ||
| Frequency of symptoms of ovarian cancer in women presenting to primary care clinics | Q33978981 | ||
| Serotonin signaling is altered in irritable bowel syndrome with diarrhea but not in functional dyspepsia in pediatric age patients. | Q33987389 | ||
| The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review | Q34016487 | ||
| Influences of Dietary and Environmental Stress on Microbial Populations in the Murine Gastrointestinal Tract | Q34105660 | ||
| Treatment of irritable bowel syndrome: a review of randomised controlled trials | Q34130605 | ||
| Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS | Q34152148 | ||
| Presentations of adult celiac disease in a nationwide patient support group | Q34196177 | ||
| Gut feelings: the emerging biology of gut-brain communication | Q34199959 | ||
| A single-blind trial of reflexology for irritable bowel syndrome. | Q34221184 | ||
| Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns | Q34271456 | ||
| Utilization patterns and net direct medical cost to Medicaid of irritable bowel syndrome | Q34285264 | ||
| Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome. | Q34297954 | ||
| IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior | Q34320278 | ||
| Bran and irritable bowel syndrome: time for reappraisal | Q34322516 | ||
| Irritable bowel syndrome and surgery: a multivariable analysis | Q34325911 | ||
| Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis | Q34325920 | ||
| U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact | Q34353536 | ||
| Defining the predictors of the placebo response in irritable bowel syndrome | Q34402513 | ||
| The placebo effect in irritable bowel syndrome trials: a meta-analysis | Q34421382 | ||
| Basic pathophysiologic mechanisms in irritable bowel syndrome | Q34468067 | ||
| Perceived food intolerance in subjects with irritable bowel syndrome-- etiology, prevalence and consequences | Q34481544 | ||
| Chronic gastrointestinal symptoms and quality of life in the Korean population | Q37397015 | ||
| The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease | Q37490320 | ||
| Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis | Q37496549 | ||
| Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care | Q37540318 | ||
| An update on irritable bowel syndrome: from diagnosis to emerging therapies | Q37811753 | ||
| Epidemiology of IBS. | Q37844827 | ||
| Symptom-based diagnostic criteria for irritable bowel syndrome: the more things change, the more they stay the same | Q37844831 | ||
| Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective | Q37852406 | ||
| Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis | Q37878858 | ||
| Severity in irritable bowel syndrome: a Rome Foundation Working Team report | Q37900126 | ||
| The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis | Q37951770 | ||
| Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis | Q37994513 | ||
| Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome | Q38029994 | ||
| Prevalence of gastro-esophageal reflux-type symptoms in individuals with irritable bowel syndrome in the community: a meta-analysis | Q38049118 | ||
| Functional dyspepsia--symptoms, definitions and validity of the Rome III criteria | Q38080665 | ||
| Symptoms of irritable bowel syndrome in a British urban community: consulters and nonconsulters | Q39239708 | ||
| Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. | Q39311968 | ||
| Meta-analysis: The treatment of irritable bowel syndrome | Q39372719 | ||
| Diagnostic criteria in IBS: useful or not? | Q39566201 | ||
| Epidemiologic study of the irritable bowel syndrome in Beijing: stratified randomized study by cluster sampling. | Q39589757 | ||
| Irritable Bowel Syndrome and Health-Related Quality of Life: A Population-Based Study in Calgary, Alberta | Q39647523 | ||
| Prevalence, sociodemography, and quality of life of older versus younger patients with irritable bowel syndrome: a population-based study | Q39751875 | ||
| A population-based study of irritable bowel syndrome in a non-Western population | Q39847065 | ||
| The prevalence and clinical characteristics of primary headache in irritable bowel syndrome: a subgroup of the functional somatic syndromes | Q40167482 | ||
| Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak | Q40289488 | ||
| The irritable bowel syndrome: long-term prognosis and the physician-patient interaction | Q40650690 | ||
| Intestinal motility in irritable bowel syndrome: is IBS a motility disorder? Part 1. Definition of IBS and colonic motility | Q40861862 | ||
| The epidemiology of functional gastrointestinal disorders in North America | Q40948747 | ||
| Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials. | Q40952124 | ||
| Why do people sue doctors? A study of patients and relatives taking legal action | Q41029565 | ||
| Tolerance for rectosigmoid distention in irritable bowel syndrome | Q41227327 | ||
| Predictors of treatment outcome after cognitive behavior therapy and antispasmodic treatment for patients with irritable bowel syndrome in primary care | Q43121926 | ||
| Epidemiology of FGID symptoms in Japanese general population with reference to life style | Q43327913 | ||
| Initial validation of a bowel symptom questionnaire and measurement of chronic gastrointestinal symptoms in Australians | Q43329459 | ||
| A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome | Q43330065 | ||
| Kruis scoring system and Manning's criteria in diagnosis of irritable bowel syndrome: is it better to use combined? | Q43331332 | ||
| Visceral hypersensitivity following cold water intake in subjects with irritable bowel syndrome | Q43335249 | ||
| A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome | Q43341145 | ||
| Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea | Q43343970 | ||
| New clinical method for distinguishing D-IBS from other gastrointestinal conditions causing diarrhea: the LA/IBS diagnostic strategy | Q43367460 | ||
| Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications | Q43437812 | ||
| Food-related gastrointestinal symptoms in the irritable bowel syndrome | Q43539583 | ||
| Serotonin transporter gene polymorphism in irritable bowel syndrome | Q44074824 | ||
| Dyspeptic symptoms and gastric emptying in the irritable bowel syndrome | Q57004953 | ||
| A History of Abuse in Community Subjects with Irritable Bowel Syndrome and Functional Dyspepsia: The Role of Other Psychosocial Variables | Q60618383 | ||
| Bloating and Distension in Irritable Bowel Syndrome: The Role of Gastrointestinal Transit | Q60707831 | ||
| Analysis of the Fecal Microbiota of Irritable Bowel Syndrome Patients and Healthy Controls with Real-Time PCR | Q63242386 | ||
| Irritable bowel syndrome. Still far from a positive diagnosis | Q67742698 | ||
| Sexual and physical abuse in women with functional or organic gastrointestinal disorders | Q68603886 | ||
| Prognosis in the irritable bowel syndrome: a 5-year prospective study | Q69896917 | ||
| Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism | Q72164304 | ||
| Increased mast cells in the irritable bowel syndrome | Q73024484 | ||
| Abnormal propagation pattern of duodenal pressure waves in the irritable bowel syndrome (IBS) [correction of (IBD)] | Q73533366 | ||
| Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention | Q73719427 | ||
| Abdominal pain, bloating, and diarrhea in the United States: prevalence and impact | Q73946175 | ||
| The irritable bowel syndrome | Q74022883 | ||
| Chronic diarrhea: identifying a new syndrome | Q74194774 | ||
| Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds | Q74262429 | ||
| Activation of the mucosal immune system in irritable bowel syndrome | Q74262437 | ||
| Presidential address: Gastrointestinal illness and the biopsychosocial model | Q74642977 | ||
| Lipid-induced intestinal gas retention in irritable bowel syndrome | Q74669850 | ||
| Psychological factors in the irritable bowel syndrome | Q75230300 | ||
| Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care | Q77160925 | ||
| Antibiotics increase functional abdominal symptoms | Q77540914 | ||
| Physical and psychological stress in rats enhances colonic epithelial permeability via peripheral CRH | Q77655279 | ||
| A re-examination of the relationship between abuse experience and functional bowel disorders | Q78044143 | ||
| Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome | Q78582159 | ||
| Increased prevalence of irritable bowel syndrome in patients with bronchial asthma | Q78852531 | ||
| Symptomatic overlap between irritable bowel syndrome and microscopic colitis | Q79502926 | ||
| Prevalence of irritable bowel syndrome in a multi-ethnic Asian population | Q79780595 | ||
| Psychosocial factors are linked to functional gastrointestinal disorders: a population based nested case-control study | Q79829157 | ||
| Correlation between symptoms of the irritable bowel syndrome and the response to the food extract skin prick test | Q79986934 | ||
| Influence of genetics on irritable bowel syndrome, gastro-oesophageal reflux and dyspepsia: a twin study | Q80349914 | ||
| Neonatal maternal separation of rat pups results in abnormal cholinergic regulation of epithelial permeability | Q80351879 | ||
| Long-term alterations of colonic nerve-mast cell interactions induced by neonatal maternal deprivation in rats | Q80492355 | ||
| Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study | Q80748001 | ||
| Food-specific IgG4 antibody-guided exclusion diet improves symptoms and rectal compliance in irritable bowel syndrome | Q81084123 | ||
| Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices | Q81397176 | ||
| Prevalence of functional gastrointestinal disorders in women who report domestic violence to the police | Q81725900 | ||
| The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype | Q82081531 | ||
| Comparison of lactulose and glucose breath test for diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome | Q83800501 | ||
| [Irritable bowel syndrome and inflammatory bowel disease: Is there a connection?] | Q83831202 | ||
| Mucosal barrier defects in irritable bowel syndrome. Who left the door open? | Q83985162 | ||
| Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome | Q84705462 | ||
| Small intestinal bacterial overgrowth | Q85179529 | ||
| Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome | Q34512846 | ||
| Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes | Q34537744 | ||
| Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. | Q34562820 | ||
| The functional gastrointestinal disorders and the Rome III process | Q34567301 | ||
| Irritable bowel syndrome in twins: genes and environment | Q34569806 | ||
| The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota | Q34596449 | ||
| Abnormal endogenous pain modulation and somatic and visceral hypersensitivity in female patients with irritable bowel syndrome | Q34604909 | ||
| Current understanding of gastrointestinal immunoregulation and its relation to food allergy | Q34649134 | ||
| Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis | Q34657632 | ||
| Visceral perception: inflammatory and non-inflammatory mediators | Q34699790 | ||
| A role for inflammation in irritable bowel syndrome? | Q34699809 | ||
| Idiopathic bile acid malabsorption: qualitative and quantitative clinical features and response to cholestyramine | Q34753929 | ||
| Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives | Q34873414 | ||
| Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study | Q34889324 | ||
| A systematic review of tegaserod for the treatment of irritable bowel syndrome | Q34969799 | ||
| Biopsychosocial model of irritable bowel syndrome | Q34976207 | ||
| An evidence-based position statement on the management of irritable bowel syndrome | Q34986401 | ||
| Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. | Q34990107 | ||
| The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review | Q34993716 | ||
| Systematic review on the management of irritable bowel syndrome in North America. | Q34993728 | ||
| AGA technical review on irritable bowel syndrome | Q35010302 | ||
| Treating irritable bowel syndrome: overview, perspective and future therapies | Q35047051 | ||
| A systematic review of alternative therapies in the irritable bowel syndrome | Q35063731 | ||
| Pharmacologic therapy for the irritable bowel syndrome | Q35124253 | ||
| Suppression of HTLV-1 replication by Tax-mediated rerouting of the p13 viral protein to nuclear speckles | Q35164261 | ||
| The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls | Q35268912 | ||
| Is the association between irritable bowel syndrome and abuse explained by neuroticism? A population based study | Q35348858 | ||
| The role of psychological and biological factors in postinfective gut dysfunction | Q35354188 | ||
| Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome | Q35362266 | ||
| Scintigraphic biomarkers for colonic dysmotility | Q35384517 | ||
| Association of distinct alpha(2) adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders | Q35596567 | ||
| Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis | Q35596747 | ||
| The prevalence of fibromyalgia in other chronic pain conditions | Q35608619 | ||
| Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome | Q35660287 | ||
| P433 | issue | 34 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | irritable bowel syndrome | Q838966 |
| P304 | page(s) | 12144-12160 | |
| P577 | publication date | 2014-09-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Irritable bowel syndrome: a clinical review | |
| P478 | volume | 20 |
| Q91798949 | A Clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome |
| Q39359526 | Abdominal pain-related functional gastrointestinal disorders in children |
| Q26777279 | Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders |
| Q36113199 | Cellular and molecular effects of yeast probiotics on cancer. |
| Q26743440 | Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome |
| Q39312398 | Comparison of Resilience and Psychological Wellbeing in Women with Irritable Bowel Syndrome and Normal Women |
| Q38673055 | Conceptualizing a subtype of patients with chronic pain: The necessity of obtaining a history of sexual abuse |
| Q38473099 | Corticotropin-releasing factor receptor type 1 and type 2 interaction in irritable bowel syndrome. |
| Q90450642 | Delineating conditions and subtypes in chronic pain using neuroimaging |
| Q58775825 | Depressive symptoms in patients with irritable bowel syndrome: a meta-analysis of comparative studies |
| Q26824367 | Diet in irritable bowel syndrome |
| Q26768564 | Diet therapy for inflammatory bowel diseases: The established and the new |
| Q89524901 | Does a Minority of Children With Functional Gastrointestinal Disorders Receive Formal Diet Advice? |
| Q42918899 | Dysregulated MicroRNA Expression in Irritable Bowel Syndrome |
| Q37522698 | Economic burden of irritable bowel syndrome in China |
| Q47142867 | Effect of herbal extract granules combined with otilonium bromide on irritable bowel syndrome with diarrhoea: a study protocol for a randomised controlled trial |
| Q36310200 | Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial |
| Q39166000 | Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome |
| Q90418278 | Efficacy and safety of lactulose for the treatment of irritable bowel syndrome |
| Q26740132 | Efficacy of Chinese Herbal Medicine for Diarrhea-Predominant Irritable Bowel Syndrome: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials |
| Q38856699 | Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome. |
| Q89589667 | Epidemiology of irritable bowel syndrome and its associated factors in Saudi undergraduate students |
| Q47177925 | Gender and Weight Influence Quality of Life in Irritable Bowel Syndrome |
| Q55190074 | Heat shock protein 70 protects mouse against post-infection irritable bowel syndrome via up-regulating intestinal γδ T cell's Th17 response. |
| Q64115887 | Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of phase III trials |
| Q50223024 | Impact of the Gut Microbiota on Intestinal Immunity Mediated by Tryptophan Metabolism |
| Q36754082 | Irritable bowel syndrome among nurses working in King Abdulaziz University Hospital, Jeddah, Saudi Arabia |
| Q58792335 | Is Effective and Safe in Short-term Treatment of Irritable Bowel Syndrome: A Systematic Review and Meta-analysis |
| Q37303691 | Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome. |
| Q91809212 | Low fermentable oligosaccharides, disaccharides, monosaccharides, and polypols diet and irritable bowel syndrome in Asia |
| Q46047126 | Non-celiac gluten sensitivity: All wheat attack is not celiac |
| Q92597406 | Noninvasive Diagnosis of Irritable Bowel Syndrome via Bowel Sound Features: Proof of Concept |
| Q35586543 | Optimal management of constipation associated with irritable bowel syndrome |
| Q35843069 | Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation |
| Q92059457 | Possible role of intestinal stem cells in the pathophysiology of irritable bowel syndrome |
| Q40610960 | Prevalence and impact of irritable bowel syndrome in people with epilepsy |
| Q38542708 | Probiotic Saccharomyces cerevisiae strains as biotherapeutic tools: is there room for improvement? |
| Q95270765 | Psychotherapeutic Interventions in Irritable Bowel Syndrome |
| Q35689193 | Recent developments in the pathophysiology of irritable bowel syndrome |
| Q33469703 | Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis |
| Q47135887 | Symptom Severity Following Rifaximin and the Probiotic VSL#3 in Patients with Chronic Pelvic Pain Syndrome (Due to Inflammatory Prostatitis) Plus Irritable Bowel Syndrome |
| Q64935645 | The Microbiome and Irritable Bowel Syndrome - A Review on the Pathophysiology, Current Research and Future Therapy. |
| Q37578593 | The Role of Mast Cells in Irritable Bowel Syndrome |
| Q33468382 | The combination of oligo- and polysaccharides and reticulated protein for the control of symptoms in patients with irritable bowel syndrome: Results of a randomised, placebo-controlled, double-blind, parallel group, multicentre clinical trial |
| Q26795563 | The role of AST-120 and protein-bound uremic toxins in irritable bowel syndrome: a therapeutic perspective |
| Q64249884 | Use of Complementary and Alternative Medicine by Patients with Irritable Bowel Syndrome According to the Roma IV Criteria: A Single-Center Italian Survey |
| Q24658463 | Visceral hypersensitive rats share common dysbiosis features with irritable bowel syndrome patients |
Search more.